Search result for 'astrazeneca pharma india'

AstraZeneca receives CDSCO approval to import & sell Datopotamab Deruxtecan for HR-positive, HER2-negative metastatic breast cancer in India.

AstraZeneca partners with Sun Pharma to expand access to Sodium Zirconium Cyclosilicate (SZC) for Hyperkalaemia treatment in India.

AstraZeneca receives Indian regulator approval to market Trastuzumab Deruxtecan for HER2-positive solid tumors.

AstraZeneca receives CDSCO approval for Durvalumab, a new treatment for muscle-invasive bladder cancer in India. This marks a significant advancement in cancer care.

AstraZeneca India receives CDSCO approval for Osimertinib, a non-small cell lung cancer treatment. The drug offers a new treatment option for patients with Stage III NSCLC.

AstraZeneca Pharma India has surrendered marketing authorization for Olaparib (Lynparza) in India due to commercial reasons. The drug is indicated for metastatic castration-resistant prostate cancer.

AstraZeneca Pharma India has received approval to import and sell sodium zirconium cyclosilicate (Lokelma) for treating hyperkalemia in adults in India. The drug is indicated for the treatment of...

AstraZeneca Pharma India receives approval to import and distribute Lynparza, an anti-cancer drug, for the treatment of advanced endometrial cancer in India.

AstraZeneca Pharma India's net profit for Q2 FY25 declined 27% to Rs 38 crore, while revenue rose to Rs 408 crore. The company's shares closed 3.74% lower on the BSE.

AstraZeneca Pharma India reported a net loss of Rs 12 crore for the first quarter ended June 30, 2024, compared to a profit of Rs 54 crore in the same period last year. Total income for the quarter...